• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

News of Note—Bavarian Nordic, FluGen and more

fiercepharmaSeptember 28, 2018

Tag: news , Note

Here is some other vaccine news of note for the week:

> Bavarian Nordic shipped Imvanex smallpox vaccine doses to England after authorities there recorded monkeypox cases. Release

> The National Institutes of Health is supporting phase 1 testing of a broadly protective flu vaccine developed by FluGen. Release

> Sinovac reports that the U.S. Department of Justice has closed an investigation into the company. Release

> In a preclinical study, an experimental H3N2 flu DNA vaccine from Inovio elicited antibody responses and protected against a heterologous lethal challenge. Release

o apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Ganovo gets enrolled in basic medical Insurance of Tianjin

Next:Pall, and G-CON Manufacturing Announce Collaboration

Related News

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

News of Note—Bavarian Nordic, FluGen and more | Pharmasources.com

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

You may like
More>>

(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol,(3aR,4S,6R,6aS)-6-aMino

(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol,(3aR,4S,6R,6aS)-6-aMino
notecan HCL

notecan HCL
Irinotecan Hydrochloride

Irinotecan Hydrochloride
DINOTEFURAN

DINOTEFURAN
Irinotecan HCl

Irinotecan HCl
Irinotecan

Irinotecan
trans-3-methyl-4-aminotetrahydropyran hydrochloride

trans-3-methyl-4-aminotetrahydropyran hydrochloride
Note blowing machine

Note blowing machine
Irinotecan

Irinotecan
Irinotecan Hydrochloride other active pharmaceutical ingredients

Irinotecan Hydrochloride other active pharmaceutical ingredients

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service